Nestlé and The United Nations...
EraCal Therapeutics, the Biotech Company Developing Solutions to Different Diseases, Joins SFNV
EraCal Therapeutics, the Biotech Company Developing Solutions to Different Diseases, Joins SFNV
The preclinical biotech startup, EraCal Therapeutics, which develops drugs using cutting-edge science to treat health and obesity issues, has joined the SFNV.
Switzerland, February 2021 – EraCal Therapeutics, a Swiss producer of biotechnology drugs using cutting-edge technology to treat metabolic syndrome, has joined the SFNV. The company is currently focusing on a pipeline of appetite suppressants to tackle obesity and its metabolic complications. Its lead molecule, Era-107, is an oral appetite suppressor with superior efficacy and safety profile, as demonstrated in three vertebrate species. EraCal is now preparing to carry out further toxicology studies ahead of first-in-human trials.
For more information:
E-mail : info@eracal.ch
Latest Members
World Food Academy 4 Sustainable Food Systems founded for knowledge sharing and capacity building
BIOKET 2026: Fribourg Shines on the International Bioeconomy Stage
For the first time in Switzerland,...
Ecorobotix Reaches Milestone: 1,000 ARA Ultra-High Precision Sprayers Sold Worldwide
From the vegetable fields of Europe to...








